Immunology Investor Event

Dupixent: Atopic Dermatitis Child 6-11yo Number of patients (thousands) Prevalence Treated Moderate-to-Severe Uncontrolled Moderate-to-Severe 2,457 1,985 718 894 1,612 320 Biologics eligible 88 74 162 2,305 2,853 4,290 5,310 sanofi Assuming eligibility limited to severe uncontrolled in pediatric indications. EU Biologic eligible was derived from moderate-to-severe 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 US Europe(1) Source: Sanofi analysis (1) Germany, France, Italy, Spain & United Kingdom. 4 Immunology Investor Event

View entire presentation